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data about the manner in which PAM visualizes different tumor types.
CONCLUSIONS:Using expert elicitation prior distributions for sensitivity and spec-
ificity of PAM were obtained. This evidence could be used in early health economic
models to establish cost-effectiveness. However, experts expressed difficulties es-
timating the performance based on limited data. The expression of uncertainty
surrounding their beliefs reflects the infancy of the diagnostic method, however
further clinical trials should be commissioned to indicate whether these results are
valid. Before that, the use of the elicited priors in health economic models requires
careful consideration.
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OBJECTIVES: A small number of patients with minor head injury deteriorate, re-
sulting in serious injury or death. Clinical features are often used to identify which
patients with minor head injury are likely to deteriorate and therefore need CT
scanning. To estimate the value of these characteristics for diagnosing intracranial
injury (including the need for neurosurgery) in adults, children and infants, a sys-
tematic review and meta-analysis of diagnostic accuracy was undertaken.
METHODS: Citations were identified through electronic searches of several key
databases, including MEDLINE, from inception to March 2010. Cohort studies of
patients with minor head injury (Glasgow Coma Score [GCS], 13-15) were selected if
they reported data on the diagnostic accuracy of individual clinical characteristics
for intracranial or neurosurgical injury. Study selection, quality assessment and
data extraction were performed by one reviewer and checked by at least another.
Where results allowed, pooled sensitivity, specificity and likelihood ratios were
estimated through meta-analysis. RESULTS: Data were extracted from 71 studies
(with cohort sizes ranging from 39 to 31694 patients). The most useful clinical
characteristics for identifying those with intracranial injury were depressed or
basal skull fracture in both adults and children (positive likelihood ratio [PLR],10).
Other useful characteristics in adults or children included focal neurological defi-
cit, post traumatic seizure (PLR5), persistent vomiting, and coagulopathy (PLR 2 to
5). Characteristics that had limited diagnostic value included loss of consciousness
and headache in adults and scalp haematoma and scalp laceration in children. Few
studies were undertaken in children and even fewer reported data for neurosurgical
injuries. CONCLUSIONS: Amongst other characteristics, depressed or basal skull
fracture indicated increased risk of intracranial injury and the need for CT scan-
ning in adults and children. Other characteristics, such as headache in adults and
scalp laceration of haematoma in children, do not reliably indicate increased risk.
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OBJECTIVES: Randomized clinical trial (RCT) evidence comparing cervical and
lumbar total disc arthroplasty (TDA) with interbody fusion for degenerative disc
disease (DDD) has been provided for different devices by FDA Investigational De-
vice Exemption (IDE) studies. A synthesis of this evidence is needed for decision
makers to select the appropriate intervention. This study aims to synthesize cur-
rent clinical evidence on TDA and evaluate its relative efficacy and safety to inter-
body fusion.METHODS:A systematic search of Medline and Cochrane library iden-
tified 6 RCTs comparing TDA with fusion. These FDA IDE studies on lumbar (3) and
cervical TDA (3), had similar designs and patient characteristics and allowed for
pooling the outcomes. Efficacy was assessed by the FDA agreed outcomes: 1)  15
points improvement in neck disability index (NDI, cervical) or Oswestry disability
index (ODI, lumbar); 2) neurological success; 3) no subsequent surgery or interven-
tion classified as “failure;” and 4) overall success: a composite measure of the
previous outcomes and the absence of major adverse events. Comparative data
were synthesised using a Bayesian meta-analytical approach. In contrast to a fre-
quentist analysis, a Bayesian approach allows for calculating the probability of
which intervention is the best and is therefore more intuitive for decision making.
As a base case scenario a random effects analysis was performed on the intention
to treat (ITT) data. RESULTS: The probability of lumbar and cervical TDA of having
better outcomes than fusion at 2 years was 91% and 96% for overall success; 76% for
ODI and 89% for NDI; 89% and 96% for neurological success; and 61% and 97% for
secondary surgery, respectively. CONCLUSIONS: Based on this analysis, both lum-
bar and cervical TDA are likely to provide a greater net improvement relative to
their respective interbody fusion techniques for single level DDD within 2 years in
the elective patients.
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OBJECTIVES: In poorly-controlled patients with NITDM the Structured Testing Pro-
tocol (STeP) study has shown improved HbA1c outcomes of a structured testing
group (STG) versus enhanced usual care that included unstructured SMBG (active
control group (ACG)) at overall cost neutrality over one year. This work analyzes
HbA1c and testing frequencies in previously non active testers. METHODS: The
underlying assumption of this exploratory analysis is that not active testers (STG:
n80; ACG: n61) - the study participants who did not test in the week before the
study – do in general not test systematically and might be particularly responsive to
structured SMBG. For both groups HbA1c and the testing frequencies were calcu-
lated based on meter download data. RESULTS: At baseline both groups did not
differ in any characteristic. Baseline HbA1c was 9.1 (Standard deviation1.2)%. In not
active testers ITT analysis revealed a 0.59% (95%-CI: 0.07 to 1.11; p0.03) larger
HbA1c difference in STG than in ACG (STG: 1.71% (2.06, 1.37); ACG: 1.12%
(1.51,0.73)). STG performed significantly fewer tests/day than ACG (mean 0.72
vs. 0.96, p0.04). This equates to a 25% difference in annual test strip consump-
tion between the STG (263 tests/year) and ACG (350 tests/year). While a relatively
high test frequency was imposed by the study protocol in the beginning of the STeP
study, in last study quarter average testing was 0.63 per day in STG and 0.79 per day
in ACG (n.s.) (equivalent to 230 vs. 288 per year). CONCLUSIONS: Structured SMBG
in not active testers was associated with higher reductions in HbA1c compared to
standard SMBG use and compared to the overall STeP population. The use of struc-
tured SMBG may be especially cost-effective in terms of HbA1c reduction per test
strips used in patients with poorly controlled NITDM who do not show a history of
consistent SMBG use.
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OBJECTIVES: Commonly used metals for MFSs are titanium (T), stainless steel (SS)
and cobalt-chrome (CC). There is no consensus on the best type of MFSs in THR.
This research sought to identify which metal would achieve better patient
outcomes. METHODS: Systematic review of MEDLINE and CENTRAL for ran-
domised controlled trials (RCTs) and comparative observational studies (OS) in
adult patients with OA undergoing THR reporting any of the following: failure/
revision surgery, implant loosening, patient pain. Searching was restricted to Eng-
lish-language and was completed in June 2011. Identified studies were assessed for
quality using the Cochrane Risk of Bias Tool. Meta-analysis was conducted using
Peto odds ratio (OR), which performs better than other approaches at estimating
ORs when there are several studies with no events in one or both arms. RESULTS:
Of the 1,934 papers identified, 13 studies were included in the analysis: 2 RCTs and
11 OS. Direct comparison demonstrated outcomes were more likely with TvsCC:
failure/revision (OR3.10, 95% Confidence Interval [95%CI]: 2.24-4.29); loosening
(OR3.49, 95%CI: 2.35-5.17); pain (OR1.88, 95%CI: 1.43-2.46). Direct comparison of SS
was only reported in one study with CC and only with revision where SS had
increased risk (OR1.32, 95%CI: 1.13-1.55. Adjusted indirect comparison of TvsSS
demonstrated increased risk with T for failure/revision (OR2.35, 95%CI: 1.64-3.36).
Significant heterogeneity was identified in the direct comparison of TvsCC for fail-
ure/revision (I265%, p0.004) and pain (I280%, p0.002), with none identified for
loosening (I20%, p0.34). Exploratory subgroup analyses by region where studies
were conducted, cemented or uncemented stems, patient age, and study size,
failed to generate a hypothesis for the potential cause of the heterogeneity.
CONCLUSIONS: The available evidence suggests that stems made from cobalt-
chrome are likely to perform better and put the patient at less risk of requiring a
revision procedure than stems made from titanium or stainless steel.
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OBJECTIVES: To analyze the best available scientific evidence on the accuracy and
usefulness of ambulatory monitoring of glycated hemoglobin in diabetic patients
with A1CNow
®
and laboratory test. METHODS: We performed searches in medical
literature databases and the best results were obtained with a search in Medline
(via Pubmed), with the keywords: (“Point-of-Care Systems” [Mesh] AND (“Diabetes
Mellitus” [Mesh] OR “ Diabetes Mellitus, Type 2” [Mesh] OR “Diabetes Mellitus, Type
1” [Mesh] OR “Diabetes Complications” [Mesh] OR “Diabetes, Gestational” [Mesh]))
AND “The Hemoglobin, glycosylated” [Mesh] AND ( “humans” [MeSH Terms] AND
(Português 
 OR Spanish 
)). We selected two studies on accuracy and five trials on
the usefulness of the test. RESULTS: Related to the accuracy, A1CNow
®
proved to
be accurate compared with laboratory tests, being the best correlation between the
methods established between A1C values between 7 and 8.5%. Related to the use-
fulness, studies showed that the availability of HbA1c results during the visit im-
proves the decision-making by physicians. In one clinical trial that specifically
investigated the usefulness of A1CNow
®
, active titration of insulin based on weekly
visit and monitoring of A1c by A1CNow
®
led to a greater percentage of patients
achieving A1C7% at the end of follow-up compared to the group which was based
on laboratory tests (41% vs. 36%, p 0.0001). CONCLUSIONS: Based on the best
evidence available (evidence level: 1B and intensity of recommendation: A), the use
of A1CNow
®
for ambulatory monitoring of glycated hemoglobin in diabetic pa-
tients is accurate and reliable compared to the alternative diagnostic laboratory
and useful in relation to the improvement of HbA1c levels.
A245V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
